Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capromorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capromorelin SCHEMBL3245235 | 1.00 | GHSR (1.00) | GHSRUGCG | |
| Capromorelin SCHEMBL1147592 | 1.00 | GHSR (1.00) | GHSRUGCG | |
| Capromorelin SCHEMBL14977966 | 1.00 | GHSR (1.00) | GHSRUGCG | |
| Capromorelin SCHEMBL5246732 | 1.00 | GHSR (1.00) | GHSRUGCG | |
| Capromorelin SCHEMBL5245758 | 0.99 | GHSR (0.98) | GHSRUGCG | |
| Capromorelin SCHEMBL5245765 | 0.99 | GHSR (0.98) | GHSRUGCG | |
| Capromorelin SCHEMBL5245768 | 0.99 | GHSR (0.98) | GHSRUGCG | |
| Capromorelin SCHEMBL5253167 | 0.97 | GHSR (0.94) | GHSR | |
| Capromorelin SCHEMBL5253173 | 0.97 | GHSR (0.94) | GHSR | |
| Capromorelin SCHEMBL20292027 | 0.96 | GHSR (0.93) | GHSRUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | HTT, SNCA, NLN | GHSR 64/4885UGCG 1092/4885 |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | ATP6V1B2, GHSR, CRH | GHSR 2/4885UGCG 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.